Allergan's Fishing For Deals, But Don't Expect A Big Catch

Allergan will use its $36bn in after-tax cash and equity from the sale of its generics business to Teva to reduce debt, buy back shares of its stock, and to acquire companies or assets, but don't expect Allergan to catch any big fish in its deal-making net.